VRP Verona Pharma Plc

 
TIDMVRP 
 
 
   Data release and conference call on Monday January 13, 2020 
 
   LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, will release results on Monday, 
January 13, 2020 at 5.00 am GMT from a Phase 2b dose-ranging study 
evaluating nebulized ensifentrine as an add-on to treatment with a long 
acting bronchodilator in patients with moderate-to-severe COPD. Also on 
January 13, 2020, Jan-Anders Karlsson, PhD, CEO of Verona Pharma, will 
host an investment community conference call to discuss the data. 
 
   Conference call and Webcast Information 
 
   Analysts and investors may participate in the conference call by using 
the conference ID and numbers below: 
 
 
 
 
Date:                        Monday, January 13, 2020 
Time:                 2.00 pm GMT / 9.00 am ET / 6.00 am PST 
Conference Call ID:                                  2874368 
 
 
   -- 866 940 4574 for callers in the United States 
 
   -- 0800 028 8438 for callers in the United Kingdom 
 
   -- 0800 181 5287 for callers in Germany 
 
 
   A live webcast will be available on the Events and Presentations page on 
the Investors section of the Company's website at www.veronapharma.com 
and an audio replay will be available there for 30 days. In addition, 
copies of the data slides and press release will be available on the 
Company's website. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Verona Pharma is currently 
in Phase 2 development with three formulations of ensifentrine for the 
treatment of COPD: nebulized, dry powder inhaler, and pressurized 
metered-dose inhaler. Ensifentrine also has potential applications in 
cystic fibrosis, asthma and other respiratory diseases. For more 
information, please visit 
https://www.globenewswire.com/Tracker?data=Ra4HcoR_1YUg5_7KEanDM9CuiTNllBQLVfG9qZUPh8a2esaqBsZt0JNkZHkrAwMNojJoNuYe0wy3bzufPyS1E_wdlGccjUCO7I1mcyCalQE= 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, the development of ensifentrine, the 
progress and timing of clinical trials and data, estimates of medical 
costs for COPD, the potential for ensifentrine to be a  first-in-class 
phosphodiesterase 3 and 4 inhibitor, and to be the first therapy for the 
treatment of respiratory diseases to combine bronchodilator and 
anti-inflammatory activities in a single molecule, and the potential 
application of ensifentrine for the treatment of cystic fibrosis, asthma 
and other respiratory diseases. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts and 
the completion of our Phase 2b trial; we may not be successful in 
developing ensifentrine for multiple indications; our ability to obtain 
approval for and commercialize ensifentrine in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; material differences between our "top-line" data and final 
data; our reliance on third parties, including clinical investigators, 
manufacturers and suppliers, and the risks related to these parties' 
ability to successfully develop and commercialize ensifentrine; and 
lawsuits related to patents covering ensifentrine and the potential for 
our patents to be found invalid or unenforceable. These and other 
important factors under the caption "Risk Factors" in our Annual Report 
on Form 20-F filed with the Securities and Exchange Commission ("SEC") 
on March 19, 2019, and our other reports filed with the SEC, could cause 
actual results to differ materially from those indicated by the 
forward-looking statements made in this press release. Any such 
forward-looking statements represent management's estimates as of the 
date of this press release. While we may elect to update such 
forward-looking statements at some point in the future, we disclaim any 
obligation to do so, even if subsequent events cause our views to 
change. These forward-looking statements should not be relied upon as 
representing our views as of any date subsequent to the date of this 
press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                        Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer             info@veronapharma.com 
David Moskowitz, VP Capital Markets Strategy & Investor 
 Relations (Investor enquiries) 
 Victoria Stewart, Director of Communications (Media 
 Enquiries) 
 
N+1 Singer                                               Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
 Finance) 
Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                         Tel: +44 (0)20 950 9144 
 (European Media and Investor Enquiries)                  verona@optimumcomms.com 
Mary Clark / Eva Haas / Hollie Vile 
 
Argot Partners                                           Tel: +1 212-600-1902 
 (US Investor Enquiries)                                  verona@argotpartners.com 
Stephanie Marks / Kimberly Minarovich / Michael Barron 
 
 
 
 
 
 

(END) Dow Jones Newswires

January 10, 2020 18:00 ET (23:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024